Mixed Mullerian Cancer PDX Models

Suitable preclinical models such as patient-derived xenografts (PDX) are needed to evaluate drugs targeting mixed mullerian cancer. PDX models are known to be the most predictive preclinical model and provide an accurate approach to evaluating an agent’s efficacy prior to entering the clinic. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MU12506Mixed Mullerian CancerNAVIEW MODEL
MU12527Mixed Mullerian CancerNAVIEW MODEL
MU12533Mixed Mullerian CancerSCLCVIEW MODEL
MU12540Mixed Mullerian CancerSCLCVIEW MODEL
MU12541Mixed Mullerian CancerNAVIEW MODEL
MU12554Mixed Mullerian CancerNAVIEW MODEL
MU12561Mixed Mullerian CancerNAVIEW MODEL
MU12575Mixed Mullerian CancerSCLCVIEW MODEL
MU12582Mixed Mullerian CancerNAVIEW MODEL
MU12603Mixed Mullerian CancerNAVIEW MODEL